Immunome Inc. (IMNM) Earnings History

Immunome Inc. - FY 2025 Earnings

Filed at: Mar 3, 2026, 4:05 PM EST|Read from source

EXECUTIVE SUMMARY

Immunome reported full-year 2025 results marked by significant progress in its pipeline, including positive Phase 3 trial results for varegacestat and ongoing Phase 1 studies for IM-1021. The company also successfully raised substantial capital, extending its projected cash runway. Key developments include planned regulatory submissions and IND submissions for new ADC programs.

POSITIVE HIGHLIGHTS

  • •

    Positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors, meeting primary and key secondary endpoints.

    positive
  • •

    Planned New Drug Application submission for varegacestat in the second quarter of 2026.

    positive
  • •

    Underwritten public offering in December 2025 raised $460.5 million in gross proceeds, extending projected cash runway into 2028.

    positive
  • •

    Three IND submissions for solid tumor-targeted ADC programs planned in 2026.

    positive
  • •

    Varegacestat generally well tolerated with a manageable safety profile.

    positive

CONCERNS & RISKS

  • •

    Net loss of $212.4 million for the year ended December 31, 2025, compared to a net loss of $293.0 million in the prior year.

    negative
  • •

    Research and development expenses increased to $177.3 million in 2025 from $129.5 million in 2024.

    negative
  • •

    General and administrative expenses increased to $43.8 million in 2025 from $33.0 million in 2024.

    negative
  • •

    In-process research and development expenses were $10.0 million in 2025, a significant decrease from $152.3 million in 2024, indicating a shift in R&D focus or milestone achievement.

    attention
  • •

    Collaboration revenue decreased to $6.9 billion in 2025 from $9.0 billion in 2024.

    negative

FINANCIAL METRICS

Revenue
Quarterly
N/A
N/A
Annual (YTD)
$6.94B
N/A
Prior year: $9.04B
Net Income
Quarterly
N/A
N/A
Annual (YTD)
$-212.39B
N/A
Prior year: $-292.96B
EPS (Diluted)
Quarterly
N/A
N/A
Annual (YTD)
$-2.43
N/A
Prior year: $-5.00
Operating Income
Quarterly
N/A
N/A
Annual (YTD)
$-224.11B
N/A
Prior year: $-305.80B
EPS (Basic)
Quarterly
N/A
N/A
Annual (YTD)
$-2.43
N/A
Prior year: $-5.00

MARGIN ANALYSIS

Margin metrics will be available once backend extracts data from insights_json

SPECIAL ITEMS & ADJUSTMENTS

FY 2025
In-process research and development expenses reflecting a development milestone associated with reporting positive topline results for the Phase 3 RINGSIDE trial of varegacestat.
+$10,000M

Special items are non-recurring events that may distort period-over-period comparisons. Analysts typically adjust for these when calculating normalized earnings.

MANAGEMENT COMMENTARY

Immunome made substantial progress in 2025, highlighted by positive Phase 3 RINGSIDE results for varegacestat, a significant milestone for patients.

— Immunome Inc., FY 2025 2025 Earnings Call

The company is focused on regulatory, manufacturing, and commercial readiness for varegacestat to position it for approval and launch.

— Immunome Inc., FY 2025 2025 Earnings Call

Advancing the antibody-drug conjugate pipeline with the ongoing Phase 1 study of IM-1021 and expecting IND submissions for three differentiated solid tumor ADCs in 2026.

— Immunome Inc., FY 2025 2025 Earnings Call

Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.

OPERATIONAL METRICS

IM-1021 Phase 1 ongoing
ongoing
IND submissions for ADC programs
3
submissions

Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.